Rocket Pharmaceuticals (RCKT) Change in Accured Expenses (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Change in Accured Expenses data on file, last reported at $2000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses changed N/A year-over-year to $2000.0; the trailing twelve-month figure through Mar 2026 stood at -$79000.0 (down 103.56% YoY), and the FY2025 full-year result was -$81000.0, down 200.0% from the prior year.
• Change in Accured Expenses fell to $2000.0 in Q1 2026, from $9.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $10.9 million in Q4 2023 to a low of -$12.2 million in Q3 2025.
• A 5-year average of $1.2 million and a median of $2.4 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 17186.67% in 2022 and sank 51566.67% in 2023, its largest moves.
• Tracing RCKT's Change in Accured Expenses over 5 years: stood at $2.5 million in 2022, then soared by 337.55% to $10.9 million in 2023, then tumbled by 147.94% to -$5.2 million in 2024, then soared by 278.49% to $9.3 million in 2025, then sank by 99.98% to $2000.0 in 2026.
• Business Quant data shows RCKT's Change in Accured Expenses at $2000.0 in Q1 2026, $9.3 million in Q4 2025, and -$12.2 million in Q3 2025.